OOIR: Observatory of International Research

Papers

(The median citation count of Leukemia & Lymphoma is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
The prognostic role of gene polymorphisms in patients with indolent non-Hodgkin lymphomas and mantle-cell lymphoma receiving bendamustine and rituximab: results of the 5-year follow-up study	42
Impact of SF3B1 mutation in myelofibrosis	36
Ruxolitinib bridging therapy to allogeneic SCT for high-risk refractory subcutaneous panniculitis-like T-cell lymphoma	35
CRLF2 and IKZF1 abnormalities in childhood hematological malignancies other than B-cell Acute Lymphoblastic Leukemia	26
Successful treatment with bortezomib, thalidomide and dexamethasone in plasma cell myeloma post-bone marrow transplant	25
Pulmonary infections in patients with acute myeloid leukemia receiving frontline treatment with hypomethylating agents	25
High seroconversion rates amongst black and Hispanics with hematologic malignancies after SARS-CoV-2 vaccination	24
Cytogenetic abnormalities in NPM1-mutated acute myeloid leukemia	22
Risk factors for mortality and re-admission of children with hematological malignancies to the intensive care unit due to sepsis	21
Efficacy and safety of voriconazole as invasive fungal infection prophylaxis in patients with acute myeloid leukemia	21
Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma	21
The mechanism of action, pharmacological characteristics, and clinical utility of the amyloid depleter birtamimab for the potential treatment of AL amyloidosis	20
CD274 structural variants for guiding treatment with PD-1 blockade in a patient with relapsed/refractory chronic active EBV transformed to NK lymphoma	20
The effect of the plasma methotrexate concentration during high-dose methotrexate therapy in childhood acute lymphoblastic leukemia	20
Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulation	20
Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 study	20
Cigarette smoking is associated with worse prognosis in myelodysplastic syndromes and hematopoietic alterations in murine models	20
Real-world associations of cytokine release syndrome and neurotoxicity with efficacy in patients receiving anti-CD-19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: the Mayo Clini	19
Hypereosinophilia after CAR T-cell therapy	19
The inherited genetic contribution and polygenic risk score for risk of CLL and MBL: a narrative review	17
Dupilumab for the treatment of refractory lenalidomide rash in patients with multiple myeloma	17
Evaluating early response assessment in extranodal natural killer/T-cell lymphoma by analyzing ΔSUVlbm between baseline and interim ¹⁸ F-FDG PET/CT scans	16
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy	16
Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma	16
Progressive multifocal leukoencephalopathy post ibrutinib therapy in relapsed chronic lymphocytic leukaemia	16

Blinatumomab for the treatment of acute lymphoblastic leukemia in a real-world setting: clinical vignettes	15
XX International workshop on chronic lymphocytic leukemia	15
Management of relapsed/refractory mantle cell lymphoma	15
Organ toxicities associated with chimeric antigen receptor T-cell therapy	15
Complete remission in a case of acute undifferentiated leukemia with novel combination therapy of FLAG-IDA and venetoclax	14
Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma	14
CD69 marks a subpopulation of acute myeloid leukemia with enhanced colony forming capacity and a unique signaling activation state	14
Shift in first-line therapies for United States Veterans Affairs (VA) patients with chronic lymphocytic leukemia (CLL)	14
MRD dynamics during maintenance therapy in 259 patients with nontransplant eligible multiple myeloma	14
Optimization of physician and specialty pharmacy clinical workflow in assessment of risk category and symptom burden in patients with myelofibrosis (MF)	14
Asparaginase therapy in patients with acute lymphoblastic leukemia: expert opinion on use and toxicity management	13
Indolent B-cell non-Hodgkin lymphomas in children: high association with inborn errors of immunity	13
Transplantation provides superior survival high risk myeloid malignancies in older patients	13
Use of PD-1 blockade in refractory/relapsed natural killer T-cell lymphomas: a systematic review and synthesis of case reports	13
New therapies for angioimmunoblastic T-cell lymphoma: a comprehensive review and analysis	13
CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study	13
Embelin inhibits viability of cutaneous T cell lymphoma cell lines HuT78 and H9 by targeting inhibitors of apoptosis	13
MicroRΝΑ analysis in patients with myelodysplastic neoplasms. Possible implications in risk stratification	12
Cost-Effectiveness of brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma	12
Chemotherapy-free approach with arsenic trioxide and all-trans retinoic acid in children with acute promyelocytic leukemia	12
Evaluation of non-research and research industry payments to pediatric hematologist/oncologists in the United States between 2013 and 2021	12
Making the case for the case report – informing physicians of intracranial hypertension as an adverse event in tyrosine kinase inhibitor treated chronic myeloid leukemia patients	12
Hyperleukocytosis associated with delayed presentation among patients with acute leukemia during the COVID-19 pandemic	12
Progressive eosinophilia and STAT5B mutation acquisition in AML treated with azacitidine and venetoclax	12
Rare HNRNPH1::ERG rearrangement in a case of de novo pediatric AML and review of cases	12
Transforming growth factor beta receptor type I (TGF-βRI) kinase inhibitors IOA-359 and IOA-360 stimulate erythropoiesis in MDS	12
Expanding the phenotypic spectrum of DDX41-related myeloid neoplasms: a case of mature plasmacytoid dendritic cell proliferation associated with acute myeloid leukemia with germline DDX41 mutation	12
A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma	12
Long-term follow up of relapsed/refractory non-Hodgkin lymphoma patients treated with single-agent selinexor – a retrospective, single center study	11
Association between plasma venetoclax trough levels and serum C-reactive protein levels in patients with acute myeloid leukemia treated with venetoclax plus azacitidine	11
Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma	11
CAR-T cell therapy in the treatment of relapsed or refractory primary central nervous system lymphoma: recent advances and challenges	11
Pretreatment serum level of interleukin-6 predicts carfilzomib-induced hypertension in relapsed/refractory multiple myeloma	11
Serum lipid trajectories in the years before a lymphoma diagnosis	11
Richter transformation – retrospective treatment outcomes analysis in Polish Adult Leukemia Study Group	11
Single-center retrospective study assessing the efficacy and safety of BeEAM (bendamustine, etoposide, cytarabine, melphalan) as conditioning regimen for autologous hematopoietic stem cell transplanta	11
PHi-RACE: PGIMER in-house rapid & cost effective classifier for the detection of BCR-ABL1 -like acute lymphoblastic leukaemia in Indian patients	11
Successful treatment with belantamab mafodotin in a heavily pretreated patient with multiple myeloma and liver extramedullary disease	11
State-wise disparities and temporal trends in acute myeloid leukemia (AML) in the United States of America (USA)	11
Analysis of albumin as a prognostic factor in HHV-8/HIV-negative Castleman disease from a multicenter study	11
CML stem cells and their interactions and adaptations to tyrosine kinase inhibitors	11
Mutational landscape in Waldenström macroglobulinemia evaluated using a next-generation sequencing lymphoma panel in routine clinical practice	10
Venetoclax-based induction therapy for primary plasma cell leukemia with high BCL-2 expression	10
The challenge of targeting key drivers of CLL and sequencing therapy in an era of experimental therapeutics	10
Donor-derived somatic genetic rescue with prolonged hematopoietic stability following sibling allogeneic stem cell transplant in SAMD9 syndrome	10
Clinical outcomes of allogeneic cell transplantation for patients with chronic myeloid leukemia	10
Correction	10
Olverembatinib in relapsed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: a study of 5 cases	10
Therapy with mosunetuzumab, a bispecific antibody for relapsed/refractory hairy cell leukemia	10
Prephase steroid use and association with dose delays and outcomes in a real-world cohort of older adults treated for diffuse large B-cell lymphoma	10

Megakaryocyte centrosomal and Golgi structural perturbations in patients with primary myelofibrosis and with RUNX1 germline mutation	10
Serological response following vaccination with BNT162b2 mRNA in patients with chronic lymphocytic leukemia	9
Low-risk relapsed acute lymphoblastic leukemia in children and young adults: what have we learnt and what’s next?	9
Off-label use of recombinant activated factor VII in hemophagocytic lymphohistiocytosis patients with major bleeding	9
Impact of chronic graft- versus -host disease on non-relapse mortality and survival	9
A PET in a time of need: toward early PET-adapted therapy in DLBCL in first relapse	9
Prediction for sustained deep molecular response for treatment-free remission	9
Limited benefit in patients with MDS receiving venetoclax and azacitidine as a bridge to allogeneic stem cell transplantation	9
Unmanipulated haploidentical donor and matched unrelated donor hematopoietic stem cell transplantation in patients with paroxysmal nocturnal hemoglobinuria: a single-center study	9
Intake of benzodiazepines in treatment naïve chronic lymphocytic leukemia patients is associate with a shorter time to first treatment	9
Achievement of durable remission of relapsed/refractory acute myeloid leukemia in a child using venetoclax monotherapy	9
[ ²¹¹ At]astatine-based anti-CD22 radioimmunotherapy for B-cell malignancies	9
The International Prognostic Score and HIV status predict red cell concentrate transfusion needs in Hodgkin lymphoma	9
COVID-19 antibody titers after tixagevimab–cilgavimab injection in patients with hematologic diseases; a single-center, prospective study	9
Outcomes and patterns of relapse with ponatinib-based therapy in patients with chronic myeloid leukemia in myeloid blast phase	9
Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression	9
The Prognostic Nutritional Index (PNI) is an independent predictor of overall survival in older patients with follicular lymphoma	9
Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison	9
Lymphocyte HLA-DR/CD-38 co-expression correlates with Hodgkin lymphoma cell cytotoxicity in vitro independent of PD-1/PD1-L pathway	9
Sun protection behaviors among adult survivors receiving hematopoietic cell transplantation: a cross-sectional survey of a single institution in Japan	9
The diagnosis of Burkitt lymphoma: how do pathologists apply criteria in daily practice?	9
Denosumab versus intravenous bisphosphonate use for hypercalcemia in multiple myeloma	8
Prospects for liquid biopsy approaches in lymphomas	8
Healthcare resource use and reimbursement amount by site of care in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell (CAR-T) therapy – a retrospective cohort stud	8
Clinicopathologic and genetic evaluation of B-lymphoblastic leukemia with intrachromosomal amplification of chromosome 21 (iAMP21) in adult patients	8
Ixazomib-induced thrombotic microangiopathy resolving without complement pathway inhibition: a case report	8
Two recurrent types of IGH ::5′ BCL2 breakpoints representing cytogenetic ins(14;18)(q32;q21q21) and t(14;18)(q32;q21), mediated by the	8
Disease response upon cessation of methotrexate in a patient with Hodgkin lymphoma treated with pembrolizumab	8
Optimal conditioning intensity: favorable outcome of a 3-day busulfan based regimen in younger acute myeloid leukemia patients	8
Ph-like acute lymphoblastic leukemia in adults: understanding pathogenesis, improving outcomes, and future directions for therapy	8
Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma	8
MEIS inhibitors reduce the viability of primary leukemia cells and Stem cells by inducing apoptosis	8
Role of the splenic microenvironment in chronic lymphocytic leukemia development in Eµ-TCL1 transgenic mice	8
Challenging diagnosis of chronic myelomonocytic leukemia (CMML) in a patient with Takayasu arteritis: case report	8
Rebound of COVID-19 infection in patients with chronic lymphocytic leukemia treated for SARS-CoV-2 with Nirmatrelvir/Ritonavir or Molnupiravir	8
The characterization and the impact of CSF pleocytosis during blinatumomab therapy for adult acute lymphoblastic leukemia	8
Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemia	8
Prognostic impact of TP53 mutations in adult acute lymphoblastic leukemia treated with a pediatric-type regimen	8
A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström’s macroglobulinemia	8
TP53 -altered higher-risk myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a distinct genetic entity with unique unmet needs	8
Clinical characteristics and outcomes of Brazilian patients with duodenal-type follicular lymphoma: a multicenter retrospective study	8
A phase 1 study of interleukin-15 in combination with avelumab in relapsed or refractory T-cell lymphoma	8
Effectiveness and safety of leukapheresis in hyperleukocytic leukemias: a retrospective multicenter study	8
Factors associated with long-term quality of life after allogenic stem cell transplantation	8
Prevalence and clinicopathological features of incidentally detected TRBC1-dim populations in peripheral blood flow cytometry	7
The impact of marginalization on diffuse large B-cell lymphoma overall survival: a retrospective cohort study	7
Single and multiple point NRAS mutations in acute myeloid leukemia: a study of 327 well molecularly characterized patients	7
White blood cell count nadir to zero following intensive chemotherapy as a predictive factor for patients with acute myeloid leukemia	7
CD5- B-cell lymphocytic leukemia –a diagnostic exclusion of splenic B-cell leukemia with prominent nuclei challenging current international consensus	7
Characteristics and clinical behavior of acute myeloid leukemia harboring rare non-A/B/D nucleophosmin ( NPM1 ) gene mutation subtypes: a single-center experience and re	7
A Shared Care Model between community and transplant centers facilitates access to allogeneic and autologous transplantation	7
Optimizing pegaspargase therapy in patients with hypersensitivity reactions	7
CALR -mutated myeloproliferative neoplasms	7
Prognostic relevance of the neutrophil/lymphocyte ratio in diffuse large B-cell lymphoma: a systematic review and meta-analysis and dose–response evidence	7
Improved overall survival over time in advanced stage mycosis fungoides: a cross-sectional study	7
Emerging drug profile: JAK inhibitors	7
Relapsed and refractory peripheral T-cell lymphoma; treatment, challenges and future perspectives	7
Allogeneic stem cell transplant outcomes between TBI-containing reduced intensity and myeloablative conditioning regimens for ALL in complete remission	7
Successful treatment of acquired von Willebrand syndrome secondary to low-grade CLL with rituximab and venetoclax	7
Impact of the addition of rituximab in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia	7
Inter-racial genetic differences in myelofibrosis: a diverse inner-city center analysis	7
Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation	7
Effects of fludarabine dosage on transplant-related outcomes in hematopoietic stem cell transplantation	7
CCND2 mutations in atypical chronic myeloid leukemia: a report of two cases	7
Response to trametinib of two pediatric myeloid malignancies cases harboring RAS mutation and monosomy 7	7
Lenalidomide, rituximab (R ² ), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma	7
Measurable residual disease dynamics holding prognostic significance in pediatric patients with RUNX1::RUNX1T1 -positive AML: results from AML-CAMS serial trials	7
Immunohistochemistry-based detection of TP53 mutations in acute myeloid leukemia: a promising high sensitivity diagnostic approach	7
Determinants of ten-year overall survival of acute myeloid leukemia: a large national cancer database analysis	7
Stem cell allografting for chronic Myeloid leukemia in the tyrosine kinase era – forgotten but not gone	7
Indolent relapse after initial aggressive B-cell lymphoma: a single institution experience in the rituximab era	7
Leukocytosis and MPNs: Where do we stand?	7
Mitigating time toxicity in lymphoma and multiple myeloma	7
Familial aspects of multiple myeloma and Waldenström macroglobulinemia: understanding the predisposition in relatives and the importance of early diagnosis	7
A de novo germline RUNX1 variant preceding development of concurrent T-lymphoblastic leukemia and myelodysplastic syndrome	6
Myeloid/lymphoid neoplasm with a novel cryptic RBPMS::FGFR1 rearrangement presenting as de novo acute leukemias	6
Evaluation of pulmonary toxicities in lymphoma patients receiving brentuximab vedotin	6
Labile CD22 and CD19 expression in a case of Philadelphia chromosome-like acute lymphoblastic leukemia	6
XXI International Workshop on CLL 2025	6
Reduced prognostic value of beta-2-microglobulin for time to first treatment in CLL patients with compromised kidney function	6

Apoptotic colitis secondary to Brentuximab Vedotin: an immune mediated adverse event responsive to steroid treatment	6
Normal and malignant cells are homogeneously distributed in the bone marrow of children	6
Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma	6
KLF2 double variants (C274Y and H210N) in a splenic B-cell lymphoma/leukemia: diagnostic insights into splenic marginal zone lymphoma and mechanistic implications	6
A case of testicular diffuse large B-cell lymphoma with late relapse in the skin: the critical role of comparative phenotypic, clonality, and cytogenetic testing	6
Therapeutic approach to patients with early stage diffuse large B cell lymphoma: retrospective, multicenter, real-life study of the ‘RTL’ (regional Tuscan lymphoma network)	6
Precision and strategic targeting of novel mutation-specific vulnerabilities in acute myeloid leukemia: the semi-centennial of 7 + 3	6
Real-world treatment adherence and persistence of FLT3 inhibitors as post-alloHCT maintenance therapy in patients with AML in the United States: a cohort study using administrative claims data	6
Severe toxicity, but long-term persistence of CAR T cells after immune checkpoint inhibitors in large B-cell lymphoma	6
Lineage switch from B-ALL to AML via an intervening MDS/MPN phase with acquisition of RBM15::MKL1 and RAD21	6
Allogeneic transplant graft source – conditioning – GVHD prophylaxis: don’t mix and match!	6
Improving outcomes in limited-stage de novo CD5+ DLBCL: systemic approaches with consolidative radiation	6
Retrospective multicenter comparative study of the efficacy and safety between R-DHAC and R-DHAOx in diffuse large B-cell lymphoma or transformed follicular or marginal zone B lymphoma into aggressive	6
Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL	6
Preclinical and clinical evaluation of Buparlisib (BKM120) in recurrent/refractory Central Nervous System Lymphoma	6
Distinct immune-response profile of Richter transformation chronic lymphocytic leukemia (CLL), defined by high expression of PD1, LAG3, TIM3 and IL-10	6
Performance of the frailty index in predicting complete remission, intensive care unit admission, and overall mortality in older and younger patients with acute myeloid leukemia receiving intensive ch	6
Polymerase chain reaction in the diagnosis of invasive aspergillosis: approaches for appropriate use	6
HHV8-Negative Effusion-Based lymphoma in a patient with recurrent HCV hepatitis status post liver transplantation	6
Pre-diagnostic serum concentrations of free light chains and risk of non-Hodgkin lymphoma in a population-based prospective study	6
Genomic landscape of T-large granular lymphocyte leukemia and chronic lymphoproliferative disorder of NK cells: a single institution experience	6
Clinical and radiological prediction models for random skin biopsy positivity in suspected intravascular large B-cell lymphoma: development and internal validation	6
Correction	6
Consistency of the efficacy of immunotherapy with histamine dihydrochloride and low-dose interleukin-2 for relapse prevention in acute myeloid leukemia	6
Progressive TP53 inactivation in an aggressive splenic diffuse red pulp small B-cell lymphoma	6
Patterns of care and outcomes of early stage I–II Hodgkin lymphoma treated with or without radiation therapy	6
Serum ferritin levels in previously untreated classical Hodgkin lymphoma: correlations and prognostic significance	6
Mutational patterns in therapy-related acute lymphoblastic leukemia subgroups: one step closer to unveiling the genetic odyssey	6
Follicular lymphoma of the lower female genital tract: an indolent and localized extranodal follicular lymphoma with mutation of TNFRSF14	6
Immunophenotypic expression and immunomodulation in minimal residual disease analysis of pediatric B acute lymphoblastic leukemia by high sensitive flow cytometry	6
Evaluation of a safe neutrophil count for cessation of intravenous antibiotics and early hospital discharge in stable, afebrile patients recovering after acute myeloid leukemia therapy or an autograft	6
Lower intensity regimens for acute myeloid leukemia: opportunities and challenges	6
Primary plasma cell leukemia in Latin America: demographic, clinical, and prognostic characteristics. A study of GELAMM group	6
Correction	6
Characterization of the calcineurin inhibitor pain syndrome in patients undergoing allogeneic hematopoietic cell transplantation	6
Tagraxofusp as first-line treatment for blastic plasmacytoid dendritic cell neoplasm	6
Hepatic Veno-occlusive disease (VOD) in multiple myeloma patient receiving Belantamab Mafodotin	6
A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia	6
Impact of autograft-absolute lymphocyte count on survival in double/triple hit lymphomas post-autologous stem cell transplantation	6
Ixazomib in addition to chemotherapy for the treatment of acute myeloid leukemia in older adults	5
TP53/PLCG2-mutated diffuse large B-cell lymphoma richter transformation (DLBCL-RT) of CLL with unusual CD2 and PD-1 expression	5
Effectiveness of prophylactic intrathecal chemotherapy and risk factors of central nervous system relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia	5
The challenge of non-transplant eligible, newly diagnosed multiple myeloma	5
Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data	5
A retrospective analysis of factors impacting survival in United States military veterans with multiple myeloma	5
Pneumocystis jirovecii pneumonia with use of brentuximab vedotin in treatment-naïve Hodgkin lymphoma	5
A randomized phase II/III study of ‘novel therapeutics’ versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomono	5
Breakthrough COVID-19 is mild in vaccinated patients with hematological malignancy receiving tixagevimab-cilgavimab as pre-exposure prophylaxis	5
Insurance-based disparities impact survival outcomes in Waldenström macroglobulinemia within the United States	5
Response to ‘blast identification in cerebrospinal fluid specimens from patients with acute myeloid leukemia: laboratory perspectives’	5
Sequential occurrence of chronic myeloproliferative and lymphoproliferative neoplasms: a collaborative retrospective study by pH-negative MPN latial group	5
Chronic lymphocytic leukemia transdifferentiated to blastic neoplasm with T/plasmacytoid dendritic cell immunophenotype	5
Rapid response to avapritinib of acute myeloid leukemia with t(8;21) andKITmutation relapse post allo-HSCT	5
Real-world treatment patterns, healthcare resource use, and costs among patients with diffuse large B-cell lymphoma: a retrospective analysis of US claims data	5
Autologous stem cell transplant for multiple myeloma: Impact of melphalan dose on the transplant outcome	5
Elicitation of societal preferences for chronic lymphocytic leukemia’s treatments: a discrete choice experiment	5
A novel ETV6::FGFR1 fusion gene in a myeloid/lymphoid neoplasm with FGFR1 rearrangement sensitive to specific FGFR1-2-3	5
Targeting the immune microenvironment in mantle cell lymphoma: implications for current and emerging therapies	5
The clinical characteristics and prognosis of patients with primary plasma cell leukemia (pPCL) according to the new IMWG definition criteria	5
The pretreatment Controlling Nutritional Status score is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma	5
RAISING revealed a heterogenous pattern of HTLV-1 clonality after HLA-haploidentical peripheral blood stem cell transplantation for ATL	5
Risk factors for influenza virus infection in patients with hematological disease	5
Lineage switch of B-lymphoblastic leukemia with KMT2A::AFF1 fusion into acute myelomonocytic leukemia under blinatumomab therapy	5
Novel treatment for mantle cell lymphoma – impact of BTK inhibitors and beyond	5
Calcific tendinopathy: an unexpected side effect of tyrosine kinase inhibitor?	5
Off-label venetoclax in combination with hypomethylating agents for post-allogeneic stem cell transplant acute myeloid leukemia relapse	5
Flow cytometry is a sensitive technique to assess marrow involvement by B cell non-Hodgkins lymphoma	5
Moving beyond traditional clinical trial endpoints: patient-reported outcomes illuminate the patient experience of novel AML therapies	5
Attempted desensitization to calaspargase pegol: a familiar approach to a new problem	5
Comparative analysis of hypomethylating agents as maintenance therapy after allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia	5
Risk of SARS-CoV-2 infection and severe COVID-19 in hematological patients who received or not pre-exposure prophylaxis with tixagevimab/cilgavimab: a target trial emulation	5
Sensitivity, specificity, and accuracy of molecular profiling on circulating cell-free DNA in refractory or relapsed multiple myeloma patients, results of MM-EP1 study	5
Innovative management of BK virus nephropathy post-HSCT: a case report and therapeutic insights	5
Follicular lymphoma: an update on biology and optimal therapy	5
Consecutive day dosing of high-dose cytarabine consolidation over 3 days is resource-efficient and safe in older adult patients with acute myeloid leukemia	5
Acalabrutinib is an effective treatment for immune thrombocytopenia associated with chronic lymphocytic leukemia, a case report	5
MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia	5
Correction	5
COVID-19 in patients with chronic lymphocytic leukemia: a Moscow observational study	5
Treatment of relapsed and refractory Waldenstrom Macroglobulinemia	5
Pembrolizumab for myelodysplastic syndromes after failure of hypomethylating agents in the phase 1b KEYNOTE-013 study	5
The prognostic role of NKG2A expression for patients with chronic myeloid leukemia after treatment discontinuation	5
Prognostic assessment value of immune escape-related genes in patients with acute myeloid leukemia	5
Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti–PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute	5
Fish evaluation of additional cytogenetic aberrations and hyperdiploidy in childhood Burkitt lymphoma	5
The characteristics and clinical prognosis analysis of ASXL1 mutations in Chinese adult patients with primary cytogenetically normal acute myeloid leukemia by next-generation sequencing	5
Therapeutic approaches for the management of higher risk myelodysplastic syndromes	5
A novel murine syngeneic CD8 peripheral T-cell lymphoma model with preclinical applications	5
Patients with plasma cell disorders undergoing autologous stem cell transplant retain their humoral response to COVID-19 vaccination but falling titers emphasize the importance of re-vaccination	5
Stereotactic radiotherapy and CART for treatment of secondary CNS lymphoma	5
Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma	5
Use of endpoints in phase III randomized controlled trials for acute myeloid leukemia over the last 15 years: a systematic review	5
Venetoclax promotes acute myeloid leukemia cells apoptosis by decreasing ac4C modification and mRNA expression of IMP3 through downregulating NAT10	5
Sarcopenia is a prognostic factor in lymphoma patients: a systematic review and meta-analysis	5
An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study	5